Lenacapavir pacfosacil

Lenacapavir pacfosacil
Clinical data
Other names	GS-4182
Identifiers
	IUPAC name 2-[2-[4-[[4-chloro-7-[2-[(1S)-2-(3,5-difluorophenyl)-1-[[2-[(2S,4R)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetyl]amino]ethyl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)-3-pyridinyl]-1-(2,2,2-trifluoroethyl)indazol-3-yl]-methylsulfonylamino]-2-methyl-4-oxobutan-2-yl]-5-methyl-3-phosphonooxyphenyl]acetic acid;
CAS Number	2937414-47-4;
PubChem CID	168826121;
UNII	ZX69MH84LB;
Chemical and physical data
Formula	C53H49ClF10N7O12PS2
Molar mass	1296.54 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=C(C(=C1)OP(=O)(O)O)C(C)(C)CC(=O)N(C2=NN(C3=C(C=CC(=C32)Cl)C4=C(N=C(C=C4)C#CC(C)(C)S(=O)(=O)C)[C@H](CC5=CC(=CC(=C5)F)F)NC(=O)CN6C7=C([C@H]8C[C@H]8C7(F)F)C(=N6)C(F)(F)F)CC(F)(F)F)S(=O)(=O)C)CC(=O)O;
	InChI InChI=InChI=1S/C53H49ClF10N7O12PS2/c1-25-14-27(19-40(74)75)43(37(15-25)83-84(76,77)78)49(2,3)22-39(73)71(86(7,81)82)48-42-35(54)11-10-32(45(42)70(68-48)24-51(57,58)59)31-9-8-30(12-13-50(4,5)85(6,79)80)65-44(31)36(18-26-16-28(55)20-29(56)17-26)66-38(72)23-69-47-41(46(67-69)53(62,63)64)33-21-34(33)52(47,60)61/h8-11,14-17,20,33-34,36H,18-19,21-24H2,1-7H3,(H,66,72)(H,74,75)(H2,76,77,78)/t33-,34+,36-/m0/s1; Key:XXPJRIWJFUQOCT-LFBNJJMOSA-N;

Lenacapavir pacfosacil is an investigational new drug that is being developed by Gilead Sciences for the treatment of HIV-1 infections. It is an orally bioavailable along-acting prodrug of lenacapavir, a HIV capsid inhibitor.^[1]^[2]

References

↑ "Lenacapavir pacfosacil". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
↑ Arens Y, Gulick RM (January 2025). "Future options for long-acting HIV treatment and prevention". Current Opinion in HIV and AIDS. 20 (1): 39–47. doi:10.1097/COH.0000000000000901. PMID 39560965.